When neoadjuvant immunotherapy meets oncogene mutations: an OASIS in the DESERT?

This is the brief introduction of the key findings from our manuscript "Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis".